Wells Fargo expects in-line EPS from Johnson & Johnson (JNJ), reaffirmed guidance

Wells Fargo analyst Larry Biegelsen reiterated an Overweight rating and $195.00 price target on Johnson & Johnson (NYSE: JNJ).

"We expect JNJ to report Q1 results that are at least in-line w/ consensus, and we expect the company to at least maintain its full year guidance. We also expect JNJ's tone on medtech procedure growth to be positive."

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $164.27 yesterday.

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Johnson & Johnson (JNJ) PT Raised to $287 at Guggenheim
• Ladenburg Thalmann Upgrades ONE Gas Inc. (OGS) to Buy